RECURSION PHARMACEUTICALS, INC.
RXRX evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $1.83B
- Lead Asset:
- REC-1245 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for RXRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RXRX
Recursion Pharmaceuticals is a clinical-stage TechBio company that uses its AI-native Recursion OS platform to discover and develop medicines, with a pipeline focused on precision oncology and rare diseases.
Key risk: Revenue decline
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 10 clinical trials for RECURSION PHARMACEUTICALS, INC..
Recursion Pharmaceuticals is a clinical-stage TechBio company that uses its AI-native Recursion OS platform to discover and develop medicines, with a pipeline focused on precision oncology and rare diseases.
- Cash & equivalents of $545.7M as of 2026-06-30 [sec]
- Total revenue of $7.7M and net loss of -$131.0M for the quarter ended 2026-06-30 [sec]
- Shareholders' equity of $915.0M as of 2026-06-30 [sec]
- Pipeline includes wholly-owned programs such as REC-4881 (MEK1/2), REC-1245 (RBM39), REC-617 (CDK7), and REC-7735 (PI3Kα H1047R) [sec_mda · as of 2026-05-06]
- Partnerships with Bayer, Sanofi, Merck KGaA, and Genentech [sec_mda · as of 2025-11-05]
What works
- End-to-end AI-native platform (Recursion OS) integrating biology, design, and clinical development, enabling rapid translation of insights into clinical candidates [sec_mda · as of 2026-02-25]
- Diversified pipeline with multiple clinical-stage programs in precision oncology and rare diseases, including REC-4881 which provided first clinical validation of the platform [sec_mda · as of 2026-02-25]
- Strategic partnerships with major biopharma companies (Bayer, Sanofi, Merck KGaA, Genentech) for neuroscience, inflammation, and other areas [sec_mda · as of 2025-11-05]
- Strong cash position of $545.7M as of 2026-06-30 provides runway for pipeline advancement [sec]
What to weigh
- Net loss of -$131.0M for the quarter ended 2026-06-30, with revenue declining to $7.7M from $19.22M a year earlier [sec] [news · published 2026-08-05]
- Most pipeline programs are still in early clinical or preclinical stages, with no approved products generating revenue [sec_mda · as of 2026-05-06]
- Reliance on partnerships for some programs may limit full value capture and introduces dependency on partner decisions [sec_mda · as of 2025-11-05]
From the filings
Quoted directly from source documents.
REC-4881 as first clinical validation of the platform
“REC-4881 (MEK1/2): Provided the first clinical validation of the Recursion OS from a novel phenotypic insight”
SEC MD&A · February 25, 2026
Q2 2026 financial results
“revenue falling to US$7.67 million from US$19.22 million a year earlier, while its net loss narrowed to US$131.01 million”
News · August 5, 2026
Catalyst timeline
- 2022-03-17 · Phase 2 start for REC-994 (CCM) — Double-blind, placebo-controlled trial in 60 participants with cerebral cavernous malformation.
- 2022-06-20 · Phase 3 start for REC-2282 (NF2) — Phase 2/3 study in participants with progressive NF2 mutated meningiomas.
- 2023-07-06 · Phase 2 start for GTA — Phase 1/2 open-label study to assess safety, PK, and anti-tumor activity.
Risks & what to watch (3)›
Key risks
- Revenue decline — Revenue fell to $7.7M in Q2 2026 from $19.22M a year earlier, indicating volatility in partnership income [news · published 2026-08-05]
- No approved products — All pipeline programs are clinical or preclinical; no marketed drugs generating revenue [sec_mda · as of 2026-05-06]
- High cash burn — Net loss of $131M in a single quarter implies significant cash consumption, though $545.7M cash provides near-term runway [sec]
What to watch
- REC-4881 regulatory update expected in 2H26 and additional Phase 1b/2 data in 1H27 [sec_mda · as of 2026-05-06]
- REC-1245 additional Phase 1 dose escalation data expected in 2H26 [sec_mda · as of 2026-08-05]
- REC-7735 (PI3Kα H1047R) ZINNIA clinical study initiation in 2H26 [sec_mda · as of 2026-08-05]
- Genentech milestone update and progress on neuroscience target in joint early discovery [news · published 2026-08-05]
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run RECURSION PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RECURSION PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.33 · 0% dilution
Lead: Phase 2/Phase 3
4 candidates
No upcoming catalysts tracked
0 buys · 11 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
334
Total value held
$1.02B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 43,192,306 | $132.6M |
| ark investment management llc | 40,212,769 | $123.5M |
| state street corp | 28,490,638 | $87.5M |
| baillie gifford & co | 23,675,407 | $72.7M |
| vanguard portfolio management llc | 22,759,100 | $69.9M |
| vanguard capital management llc | 22,244,387 | $68.3M |
| softbank group corp. | 13,636,515 | $41.9M |
| geode capital management, llc | 12,275,084 | $37.7M |
| mic capital management uk llp | 9,644,032 | $29.6M |
| goldman sachs group inc | 6,065,661 | $18.6M |
Showing top 10 of 334 institutional holders of RECURSION PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 34.9%
- Days to cover
- 14.0
- Shares short
- 174,397,876
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RXRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for RECURSION PHARMACEUTICALS, INC.?
Recursion Pharmaceuticals is a clinical-stage TechBio company that uses its AI-native Recursion OS platform to discover and develop medicines, with a pipeline focused on precision oncology and rare diseases.
What is RECURSION PHARMACEUTICALS, INC.'s lead drug candidate?
RECURSION PHARMACEUTICALS, INC.'s most advanced tracked candidate is REC-1245 (Phase 1/Phase 2) for Unresectable.
Who is the CEO of RECURSION PHARMACEUTICALS, INC.?
Dr. Najat Khan Ph.D. is the chief executive officer of RECURSION PHARMACEUTICALS, INC. (RXRX).
Where is RECURSION PHARMACEUTICALS, INC. headquartered?
RECURSION PHARMACEUTICALS, INC. (RXRX) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does RECURSION PHARMACEUTICALS, INC. focus on?
RECURSION PHARMACEUTICALS, INC. develops therapies across Oncology, Rare Disease, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.